24-Jul-2026
Business Wire (Wed, 22-Jul 7:00 AM ET)
CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
Business Wire (Mon, 20-Jul 7:00 AM ET)
CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026
Business Wire (Thu, 2-Jul 4:05 PM ET)
CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer
Business Wire (Wed, 17-Jun 4:35 PM ET)
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
Business Wire (Wed, 20-May 8:30 AM ET)
CONMED Corporation Announces First Quarter 2026 Financial Results
Business Wire (Wed, 29-Apr 4:05 PM ET)
CONMED Corporation Sees Premarket Decline Following Financial Results
Market Chameleon (Thu, 6-Feb 3:34 AM ET)
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
Conmed trades on the NYSE stock market under the symbol CNMD.
As of July 24, 2026, CNMD stock price climbed to $42.68 with 406,396 million shares trading.
CNMD has a beta of 0.78, meaning it tends to be less sensitive to market movements. CNMD has a correlation of 0.05 to the broad based SPY ETF.
CNMD has a market cap of $1.32 billion. This is considered a Small Cap stock.
Last quarter Conmed reported $317 million in Revenue and $.89 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.07.
In the last 3 years, CNMD traded as high as $133.57 and as low as $31.44.
The top ETF exchange traded funds that CNMD belongs to (by Net Assets): IJR, IWM, VTI, VB, VBR.
CNMD has underperformed the market in the last year with a return of -13.5%, while SPY returned +17.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CNMD shares. However, CNMD has outperformed the market in the last 3 month and 2 week periods, returning +11.3% and +10.9%, while SPY returned +3.8% and -2.1%, respectively. This indicates CNMD has been having a stronger performance recently.
CNMD support price is $39.82 and resistance is $42.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNMD shares will trade within this expected range on the day.
